Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By About $0.18 - 8K
Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By About $0.18 - 8K
再生元製藥公司預計其第二季度的GAAP和非GAAP財務結果將包括一項約2400萬美元的收購研發支出的稅前費用，影響GAAP和非GAAP每股收益約爲0.18美元。-8K
Regeneron Pharmaceuticals Expects Its Q2 GAAP And Non-GAAP Financial Results Will Include A Pre-tax Charge Of ~$24M For Acquired In-process Research And Development, Impacting GAAP And Non-GAAP EPS By About $0.18 - 8K
再生元製藥公司預計其第二季度的GAAP和非GAAP財務結果將包括一項約2400萬美元的收購研發支出的稅前費用，影響GAAP和非GAAP每股收益約爲0.18美元。-8K
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。